| Literature DB >> 32380458 |
Neha Mehta-Shah1, Steven M Horwitz2, Stephen Ansell3, Weiyun Z Ai4, Jeffrey Barnes5, Stefan K Barta6, Mark W Clemens7, Ahmet Dogan2, Kristopher Fisher8, Aaron M Goodman9, Gaurav Goyal10, Joan Guitart11, Ahmad Halwani12, Bradley M Haverkos13, Richard T Hoppe14, Eric Jacobsen15, Deepa Jagadeesh16, Matthew A Lunning17, Amitkumar Mehta10, Elise A Olsen18, Barbara Pro11, Saurabh A Rajguru19, Satish Shanbhag20, Aaron Shaver21, Andrei Shustov22, Lubomir Sokol23, Pallawi Torka24, Carlos Torres-Cabala7, Ryan Wilcox25, Basem M William26, Jasmine Zain27, Mary A Dwyer28, Hema Sundar28, Youn H Kim14.
Abstract
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).Entities:
Mesh：
Year: 2020 PMID： 32380458 DOI： 10.6004/jnccn.2020.0022
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908